Apollo Hospitals gets NCLT order on composite scheme

Apollo Hospitals Enterprise Limited received a certified true copy of an order dated 5 May 2026 from the National Company Law Tribunal’s Division Bench II in Chennai for a composite scheme of arrangement involving four entities. The order was uploaded on the Tribunal’s website on 7 May and received by the company on 8 May. The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. ⚖️

The proposed scheme names Apollo Hospitals Enterprise Limited as the primary company, Apollo Healthco Limited and Keimed Private Limited as transferor companies, and Apollo Healthtech Limited as the resultant company. Their respective shareholders and creditors are also part of the arrangement. The filing follows an earlier company intimation dated 27 April 2026 and represents a further procedural development in the scheme process. The excerpt does not provide the scheme’s consideration, effective date, or financial impact, so those details remain important for assessing the final effect on the listed entity.

Apollo Hospitals closed at ₹7,775 on 12 Oct 2026, down 3.15%, with volume of 990,813, according to OI Charts data. The stock declined 2.6% over five sessions and 12.6% over 20 sessions, while remaining between its 52-week range of ₹6,696 and ₹9,070. In derivatives, futures open interest fell 8.3% during the session alongside the price decline, indicating long unwinding rather than fresh short build-up. The futures premium stood at 0.15%, and the put-call ratio was 0.71.

For the 27 Oct 2026 expiry, the ₹8,000 strike had the largest put open interest and was also the max-pain level, while the largest call open interest stood at ₹9,000. These levels provide the immediate derivatives backdrop: ₹8,000 is the key downside reference, while ₹9,000 marks the largest call open-interest ceiling in the available chain.

Source: scanx.trade, 13 Oct 2026

Not investment advice. For informational purposes only.